Literature DB >> 21265942

Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.

Cheng-Yuan Chen1, Tai-Yueh Lin, Chia-Chun Wang, Hua-An Shuai.   

Abstract

This study examined prolactin levels, sexual function and clinical improvement after switching to aripiprazole from risperidone. Nine schizophrenic male Chinese patients who reported risperidone-induced sexual dysfunction were studied. Clinical Global Impression Scale Scores for Severity (CGI-S), Clinical Global Impression Scale Scores for Improvement (CGI-I), Arizona Sexual Experience Scale results and serum prolactin concentrations were determined over 16 weeks. After treatment with aripiprazole, all patients showed reduced serum prolactin (26.54 ± 17.03 ng/mL to 3.71 ± 1.87 ng/mL, P=0.008) and five reported improved sexual function. Mean baseline CGI-S (5.11 ± 0.93) decreased to 3.78 ± 1.39 (P=0.010) by week 16. Compared to baseline (4.0), the mean CGI-I significantly declined by the end of the study (3.44 ± 0.53, P=0.025).
© 2010 The Authors. Psychiatry and Clinical Neurosciences © 2010 Japanese Society of Psychiatry and Neurology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21265942     DOI: 10.1111/j.1440-1819.2010.02156.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  11 in total

Review 1.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

2.  Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.

Authors:  Rachael W Taylor; Lindsey Marwood; Emanuella Oprea; Valeria DeAngel; Sarah Mather; Beatrice Valentini; Roland Zahn; Allan H Young; Anthony J Cleare
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

3.  Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.

Authors:  Zhe Lu; Yaoyao Sun; Yuyanan Zhang; Yu Chen; Liangkun Guo; Yundan Liao; Zhewei Kang; Xiaoyang Feng; Weihua Yue
Journal:  Transl Psychiatry       Date:  2022-07-05       Impact factor: 7.989

4.  Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.

Authors:  Michael J Crawford; Lavanya Thana; Rachel Evans; Alexandra Carne; Lesley O'Connell; Amy Claringbold; Arunan Saravanamuthu; Rebecca Case; Jasna Munjiza; Sandra Jayacodi; Joseph G Reilly; Elizabeth Hughes; Zoe Hoare; Barbara Barrett; Verity C Leeson; Carol Paton; Patrick Keown; Sofia Pappa; Charlotte Green; Thomas Re Barnes
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

Review 5.  Prolactin serum concentrations during aripiprazole treatment in youth.

Authors:  Daniel J Safer; Chadi A Calarge; Alan M Safer
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05-06       Impact factor: 2.576

Review 6.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

7.  Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia.

Authors:  Fatemeh Ranjbar; Homayoun Sadeghi-Bazargani; Parisa Niari Khams; Asghar Arfaie; Azim Salari; Mostafa Farahbakhsh
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-02       Impact factor: 2.570

Review 8.  Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach.

Authors:  Angel L Montejo; Rubén de Alarcón; Nieves Prieto; José Mª Acosta; Bárbara Buch; Laura Montejo
Journal:  J Clin Med       Date:  2021-01-15       Impact factor: 4.241

9.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630

Review 10.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.